Viridian Therapeutics

Yahoo Finance • 6 days ago

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced stocks to buy for the next 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gros... Full story

Yahoo Finance • 7 days ago

Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project

OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining th... Full story

Yahoo Finance • 9 days ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story

Yahoo Finance • last month

Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now. On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the... Full story

Yahoo Finance • last month

Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock posted a 12.72% increment from a year ago, and a 51.76% year-to-date decline. Based on consensus, Wall Street ana... Full story

Yahoo Finance • last month

Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $36 from $40 on April 8 but maintained a Buy rating on the sh... Full story

Yahoo Finance • last month

Viridian Metals Inc. Clarifies Disclosure

OTTAWA, Ontario, April 16, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) ("Viridian" or the "Company") wishes to clarify the disclosure in its press release dated April 15, 2026 regarding its marketing services agreement with... Full story

Yahoo Finance • last month

Viridian Announces Market Services Agreement With Outside The Box Capital

OTTAWA, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) ("Viridian" or the "Company") is pleased to announce that it has entered into a marketing services agreement (the "Agreement") effective April 15, 2026... Full story

Yahoo Finance • 2 months ago

Viridian Therapeutics price target lowered to $36 from $40 at Truist

Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts ac... Full story

Yahoo Finance • 2 months ago

Viridian Metals Secures $225,000 Maximum JEA Funding; Adopts Quarterly Reporting Exemption

OTTAWA, April 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) reports that it has been awarded $225,000 under the Junior Exploration Assistance (“JEA”) program, representing the maximum funding... Full story

Yahoo Finance • 2 months ago

Stifel sees path towards differentiation for Viridian after Amgen data

Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adj... Full story

Yahoo Finance • 2 months ago

Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot

Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week’s sustained selloff, but th... Full story

Yahoo Finance • 2 months ago

Stocks Pressured by Economic Fallout from Iran War

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.78%.  June E-mini S&P futures (ESM26) fell -0.43%, and June... Full story

Yahoo Finance • 2 months ago

Stocks to watch on Monday after market: VRDN, BSX, MTB, AL

[manhattan office building] franckreporter/iStock via Getty Images Wall Street’s major market averages closed mostly lower on Monday as investors looked to navigate the holiday-shortened trading week with eyes continuing to focus on the M... Full story

Yahoo Finance • 2 months ago

Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%.  June E-mini S&P futures (ESM26) are up +0.38%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 2 months ago

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics stock crashed Monday on "positive, but lackluster" final-phase results for its thyroid eye disease treatment. Continue Reading... Full story

Yahoo Finance • 2 months ago

Stocks Rebound as T-note Yields Tumble

The S&P 500 Index ($SPX) (SPY) today is up +0.42%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.32%.  June E-mini S&P futures (ESM26) are up +0.40%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 2 months ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 2 months ago

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5... Full story

Yahoo Finance • 2 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story